EHA 2026丨Prof. Stephen Ansell and Dr. Zhihui Li: Exploring the Immunobiology and Precision Treatment of Hodgkin Lymphoma

EHA 2026丨Prof. Stephen Ansell and Dr. Zhihui Li: Exploring the Immunobiology and Precision Treatment of Hodgkin Lymphoma

Crossing borders, exchanging insights, and exploring the frontiers of hematology. During the 2026 Congress of the European Hematology Association (EHA), Oncology Frontier – Hematology Frontier invited Dr. Zhihui Li, Director of Beijing Gaobo BoRen Hospital, and Prof. Stephen Ansell of Mayo Clinic for an in-depth discussion on the tumor immune microenvironment and precision treatment of Hodgkin lymphoma (HL).
Pujiang Prostate Cancer Academic Conference | Prof. Fangning Wan: Innovations in Local Therapy, Advances in Systemic Treatment, and Clinical Applications of Cryotherapy for Prostate Cancer

Pujiang Prostate Cancer Academic Conference | Prof. Fangning Wan: Innovations in Local Therapy, Advances in Systemic Treatment, and Clinical Applications of Cryotherapy for Prostate Cancer

The 2026 Pujiang Prostate Cancer Academic Conference was held in Shanghai from June 26–27, 2026. As treatment strategies for prostate cancer continue to evolve, local therapy has progressed beyond conventional radical surgery toward robot-assisted precision surgery with greater emphasis on functional preservation. Meanwhile, focal therapies such as cryoablation and irreversible electroporation (IRE) have emerged as promising treatment options for carefully selected patients.
Advances in ADC Therapy for Advanced Urothelial Carcinoma | Prof. Kaiwei Yang Reviews the Evolving First- and Later-Line Treatment Landscape

Advances in ADC Therapy for Advanced Urothelial Carcinoma | Prof. Kaiwei Yang Reviews the Evolving First- and Later-Line Treatment Landscape

The treatment landscape for advanced urothelial carcinoma (UC) has entered a new era. Antibody-drug conjugates (ADCs) targeting Nectin-4, HER2, and Trop-2 have rapidly transformed clinical practice, while ADCs combined with immune checkpoint inhibitors have become the new standard for first-line treatment. At the 2026 CSCO Annual Meeting, Prof. Kaiwei Yang from the Department of Urology, Peking University First Hospital presented a comprehensive overview of the current evidence supporting approved and investigational ADCs. Drawing on the latest 2026 CSCO Guidelines, he systematically reviewed first-line treatment strategies, sequencing after disease progression, breakthroughs in domestically developed ADCs, and the next generation of emerging targets, providing valuable insights into individualized treatment for advanced urothelial carcinoma.
Prof. Benkang Shi: Building Academic Synergy Across the Yellow River Region to Advance High-Quality Development of Urology in Shandong

Prof. Benkang Shi: Building Academic Synergy Across the Yellow River Region to Advance High-Quality Development of Urology in Shandong

The 3rd Yellow River Urology Congress and the 31st Academic Conference on Urology of the Shandong Medical Association were recently held, bringing together leading urologists from across China to discuss the latest advances in the field, innovations in clinical practice, talent development, and regional collaboration.
CUDA 2026 | Prof. Xiaoying Li: From Technological Innovation to MDT Collaboration—Redefining the Landscape of Urologic Oncology

CUDA 2026 | Prof. Xiaoying Li: From Technological Innovation to MDT Collaboration—Redefining the Landscape of Urologic Oncology

The 2026 Annual Meeting of the Chinese Urological Association (CUDA) was held in Zhengzhou from June 11–14, bringing together leading experts in urology and related disciplines under the theme "Unity, Collaboration, Innovation, and Development." The meeting focused on advancing high-quality clinical research, technological innovation, multidisciplinary collaboration (MDT), and regional cooperation, while promoting the continued development of comprehensive care for urologic diseases.
BOC 2026 | Prof. Pei Dong: Kidney Cancer Enters the Era of Long-Term Survival, with New Advances in Adjuvant Therapy and Comprehensive Disease Management

BOC 2026 | Prof. Pei Dong: Kidney Cancer Enters the Era of Long-Term Survival, with New Advances in Adjuvant Therapy and Comprehensive Disease Management

In renal cell carcinoma (RCC), continued advances in targeted therapy and immunotherapy have ushered patients with advanced disease into an era of long-term survival and chronic disease management. However, important clinical challenges remain, including optimizing adjuvant treatment for high-risk patients after surgery, selecting effective therapies following immunotherapy resistance, and developing multidisciplinary models for comprehensive care throughout the disease course.
CUDA 2026 | Prof. Nianzeng Xing: Advancing Urology Through Collaboration and Innovation

CUDA 2026 | Prof. Nianzeng Xing: Advancing Urology Through Collaboration and Innovation

The 2026 Annual Meeting of the Chinese Urological Association (CUDA) was held in Zhengzhou from June 11–14, 2026. As one of China's most influential national academic meetings in urology, this year's conference adopted the theme "Collaboration and Innovation", bringing together leading domestic and international experts to discuss advances in minimally invasive surgery, robotic technology, precision medicine, and multidisciplinary cancer care, while promoting high-quality specialty development and the translation of scientific advances into clinical practice.
CUDA 2026 | Rethinking Tiered Healthcare and Multidisciplinary Care in Urology—An Interview with Prof. Zhisong He

CUDA 2026 | Rethinking Tiered Healthcare and Multidisciplinary Care in Urology—An Interview with Prof. Zhisong He

The 2026 Annual Meeting of the Chinese Urological Association (CUDA) was held in Zhengzhou under the theme "Collaboration and Innovation." The conference focused on key topics including precision diagnosis and treatment of urologic diseases, comprehensive cancer management, and multidisciplinary team (MDT) care, showcasing China's latest advances in technological innovation and the standardization of clinical practice.
CUDA 2026 | Prof. Xingyuan Xiao: Rethinking Comprehensive Urologic Cancer Management Through the Integration of Traditional Chinese and Western Medicine and MDT

CUDA 2026 | Prof. Xingyuan Xiao: Rethinking Comprehensive Urologic Cancer Management Through the Integration of Traditional Chinese and Western Medicine and MDT

The 2026 Annual Meeting of the Chinese Urological Doctor Association (CUDA 2026) was held in Zhengzhou, Henan, from June 11 to 14. Prof. Xingyuan Xiao of Zhongnan Hospital of Wuhan University has long been engaged in the clinical management and research of urologic diseases, with extensive experience in integrating traditional Chinese medicine (TCM) and Western medicine for urologic cancers and treatment-related complications.